Every compound on our shelf is here because of published, peer-reviewed research. Below: the foundational papers we point to for each. Inclusion is informational — none of this constitutes medical advice or therapeutic claims.
Synthetic pentadecapeptide derived from a sequence in human gastric juice. The most extensively studied research peptide for in-vitro tendon, ligament, and gut tissue work.
Synthetic version of a naturally occurring peptide. Research literature focuses on tissue regeneration, actin sequestration, and angiogenesis.
Long-acting growth hormone-releasing hormone (GHRH) analog. The DAC modification extends half-life to ~8 days, producing sustained pulsatile GH release in published research.
First selective ghrelin-receptor agonist studied. Research literature emphasizes its specificity for GH release without affecting cortisol, prolactin, or ACTH at typical study doses.
Non-peptide ghrelin receptor agonist active orally. Two-year clinical research has examined sustained GH and IGF-1 elevation in older adult populations.
Some research peptides appear together in the published literature because their mechanisms overlap or complement. Below: published studies for the compounds we sell as multi-vial research stacks. The references describe what the studies investigated — not how anyone should use these materials.
Multiple published studies have investigated BPC-157 and TB-500 in parallel tissue-repair models, noting complementary mechanisms — BPC-157 research has focused on angiogenesis and growth-factor receptor expression, while TB-500 literature emphasizes actin sequestration, cell migration, and angiogenesis. Inclusion here is purely informational; the studies below describe in-vitro and animal-model research.
Published pharmacokinetic research has characterized each of these GH-axis compounds independently — CJC-1295 (DAC) as a long-acting GHRH analog producing sustained pulsatile GH release, Ipamorelin as a selective ghrelin-receptor agonist with a clean specificity profile in early studies, and MK-677 as an orally active non-peptide ghrelin mimetic with multi-year clinical research on GH and IGF-1 elevation. Their combined investigation in the literature reflects overlap in mechanism rather than any combined-protocol recommendation by Roji.
The papers above describe published in-vitro and in-vivo research. Their inclusion on this page is informational only and does not represent a claim by Roji Peptides that any product is intended to diagnose, treat, cure, mitigate, or prevent any disease. All products are sold for in-vitro laboratory research and identification purposes only. Read the full disclaimer.